cadonilimab

Overview

Cadonilimab (AK104) is a bispecific monoclonal antibody simultaneously targeting PD-1 (PDCD1) and CTLA-4 (CTLA4). By co-blocking both checkpoints with a single molecule, it is intended to deliver dual immune checkpoint inhibition while potentially reducing systemic toxicity relative to combining two separate antibodies.

Evidence in the corpus

• Cadonilimab + chemotherapy in PD-1-refractory R/M NPC (NCT05790200, n=25): ORR 68%; median PFS 10.6 mo; median DOR 9.1 mo; 1-yr OS 75.6%; grade ≥3 TRAE 48% PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.